Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 18, 2005 Rich Duprey	Chiron's Sickly Forecast The flu vaccine maker further reduces its estimated dose production. With its earnings release due next week, perhaps Chiron was simply preparing investors for a jolt.
The Motley Fool December 10, 2004 Rich Duprey	Regulators Quarantine Chiron The FDA sends a warning letter on the heels of a suspension extension by British authorities. Whether shares of the pharmaceutical ultimately finish up or down, the one-two punch from U.S. and British authorities still points to an ailing company.
BusinessWeek January 31, 2005 Arlene Weintraub	Chiron's Flu Aches May Last Awhile Its vaccine rivals are gaining traction -- and its other businesses are just so-so
The Motley Fool July 28, 2005 Rich Duprey	Chiron's Tragic Quarter The biotech vaccine maker barely breaks even but boasts of its ability to meet full-year expectations.
The Motley Fool October 6, 2004 Rich Duprey	Chiron Sneezes, Investors Catch Cold British authorities shut down the pharmaceutical's only U.S. flu vaccine manufacturing facility. This may in fact be an opportunity to scoop up a beleaguered stock at fire sale prices.
The Motley Fool December 21, 2004 Rich Duprey	Chiron Requests a Second Thought Had the vaccine maker simply issued a press release with the incorrect information, it might be understandable, but investors might feel more at ease if it had gotten it right when it filed documents with the SEC.
The Motley Fool March 3, 2005 Rich Duprey	Chiron Back From the Dead British authorities give vaccine manufacturer the go-ahead to restart facility. Investors can breathe a sigh of relief.
The Motley Fool June 17, 2005 W.D. Crotty	Biotech's Apple Dumpling Gang Chiron has made a number of financial and planning mistakes in the production of its flu vaccine.
The Motley Fool September 7, 2005 Rich Duprey	Is Chiron Worth It? The vaccine maker rejects Novartis' bid of $40 a share as inadequate. How much should the pharma pay? Investors, take note.
The Motley Fool October 14, 2005 Rich Duprey	Chiron Ready to Fly Flu vaccine maker readies first shipments as flu season begins and avian flu fears rise.
The Motley Fool January 26, 2005 Rich Duprey	Chiron's Earnings Ills Flu vaccine manufacturer expected to report significantly lower profits.
The Motley Fool October 22, 2004 Rich Duprey	Chiron Reports Profit, But So What? The flu vaccine debacle overshadows the company's profits and earnings.
The Motley Fool May 27, 2005 Rich Duprey	Glaxo's Flu Vaccine Booster The drug giant's return could give the U.S. flu vaccine market a shot in the arm.
The Motley Fool May 26, 2005 Brian Gorman	Flu Vaccines' Unhealthy Competition The vaccine business is notoriously tricky. Given the nature of the business, respectable returns are predicated on high volumes. New competitors in the flu-fighting niche could make all companies worse off.
The Motley Fool July 5, 2006 Rich Duprey	Flu Vaccine Deja Vu The country's largest vaccine maker, Sanofi Aventis, gets an FDA warning letter reminiscent of the 2004 debacle.
The Motley Fool June 14, 2005 Rich Duprey	Chiron's Credit Conundrum Standard & Poor's downgrades the biotech's credit rating on seemingly old news. Why now?
The Motley Fool October 31, 2005 Rich Duprey	Chiron Not Immune to Merger The board accepts a sweetened buyout offer from Swiss pharmaceutical firm Novartis. Investors, take note.
The Motley Fool January 14, 2005 Rich Duprey	Chiron's Mythical Flu Vaccine The vaccine maker does not know when or if it will be able to start manufacturing again. Investors should pay close attention.
The Motley Fool March 16, 2006 Rich Duprey	Chiron's Shareholder Revolt Hedge funds oppose the biotech's buyout by pharmaceutical giant Novartis. Investors, take note.
The Motley Fool September 2, 2005 Rich Duprey	Will Flu Vaccine Catch Cold? The CDC says we may have as many as 97 million doses this year, but that's a best-case scenario. This year again, it's Chiron causing the uncertainty.
The Motley Fool February 14, 2005 Rich Duprey	Chiron Probe Goes Formal SEC upgrades investigation into vaccine manufacturer. Was Chiron was as surprised by the contamination debacle as investors and U.S. regulators were?
The Motley Fool October 28, 2005 Rich Duprey	Chiron's Bird Flu Contract As Asian bird flu becomes the crisis du jour, this flu vaccine biotech is awarded a hefty contract.
BusinessWeek October 25, 2004 John Carey	A Booster Shot For Vaccines New technology could speed the development of vaccines and keep the medicine chest stocked.
The Motley Fool April 4, 2006 Rich Duprey	Chiron's Booster Shot Novartis raises its bid for the biotech a second time, appeasing dissident shareholders.
The Motley Fool October 19, 2004 Rich Duprey	Chiron Crisis Creates Investor Opportunity As flu vaccine maker flames out, other companies may step in to fill the void.
BusinessWeek October 24, 2005 John Carey	New Vaccines For A Pandemic Using DNA, vast amounts of flu vaccine could be made quickly. But will the drugs work?
The Motley Fool October 29, 2004 Selena Maranjian	Flu Shots for the Elite The flu shot shortage offers some food for thought for investors. Here are some statistics showing the establishment has some problems with the priorities when it comes to the flu.
BusinessWeek January 9, 2006 Carol Matlack	Preventing The Pandemic France's Sanofi Pasteur is already signing contracts for an avian flu vaccine.
The Motley Fool October 5, 2004 Alyce Lomax	No Cheer for Chiron A U.K. regulatory body suspended its manufacturing license because of contamination. The company's misstep adds up to another rough flu season.
The Motley Fool September 21, 2005 Rich Duprey	A Shot of Reality for Chiron Novartis warns pharma it's willing to walk away from takeover bid. Does Chiron have the wherewithal to go it alone? Investors, take note.
The Motley Fool September 1, 2005 Stephen D. Simpson	Novartis Keeps Gorging Offering to buy the remainder of Chiron for $4.5 billion may up this company's execution risk over the next few quarters. Investors, take note.
The Motley Fool February 23, 2010 Brian Orelli	The End of a Swine Flu Era A Food and Drug Administration advisory panel recommended yesterday that next year's seasonal flu vaccine contain the vaccine for the H1N1 virus, aka the swine flu.
Chemistry World February 2006	Editorial: Fighting Avian Flu Participants at a world avian flu conference in Beijing committed to increasing cooperation on global vaccine and anti-viral research and development.
The Motley Fool March 2, 2005 Dave Marino-Nachison	Henry Schein Shines On Trouble with partner Chiron's full vaccines hasn't stopped Henry Schein's share rise.
Chemistry World July 24, 2009 Matt Wilkinson	Pharma's shot in the arm? As swine flu cases continue to erupt around the globe, the latest financial results from pharmaceutical companies Roche and GlaxoSmithKline reveal that sales of their antiviral drugs have soared.
The Motley Fool January 28, 2005 Rich Duprey	Chiron: What Would Warren Do? Have the pharmaceutical company's vaccine woes made it a Buffett-worthy investment yet?
The Motley Fool March 1, 2011 Brian Orelli	Uncle Sam Gives Novavax a Big Hand Up Cash is everything for a development-stage drugmaker.
Health October 2007 Sarah Clachar	Read this BEFORE you get a flu shot The flu vaccine may not be as good -- or as safe -- as you think.
The Motley Fool October 8, 2004 Rick Aristotle Munarriz	A Fool Looks Back Stern Means Sirius... Little Bunny Flu Flu... Wall-to-Wall-to-Wal-Mart... Two for the Show...
The Motley Fool October 11, 2004 Richard Gibbons	4 Ways to Profit From Catastrophes What to do when bad news strikes a company you're watching.
The Motley Fool December 7, 2004 Brian Gorman	ID Biomedical's Shot in the Arm The company appears well-positioned for the coming years, but it may be best to stay cautious on the company.
BusinessWeek April 4, 2005 Gene G. Marcial	Schein Gets Over The Flu Henry Schein, the top producer of flu vaccines in the U.S., reported notable fourth-quarter earnings despite the mandated stoppage of vaccine production last year.
The Motley Fool January 3, 2007 Matthew Crews	Henry Schein Herds Immunity The vaccine distributor hopes a strong 2007 will help revive its earnings. Value investors should put Henry Schein on their watch lists until it presents a greater margin of safety.
The Motley Fool September 7, 2005 Stephen D. Simpson	Smashing Good Deal, Eh? Glaxo's purchase of Canadian ID Biomedical will seriously augment its vaccine capabilities. Investors, take note.
The Motley Fool December 13, 2007 Brian Orelli	Merck's Vaccination Woes Merck announces it is recalling 1.2 million doses of a vaccine that immunizes children against Hib, which causes meningitis, pneumonia, and other serious infections.
American Family Physician January 15, 2004	Influenza Vaccine What is influenza?... Who is at higher risk?... What is the flu vaccine?... Is the vaccine safe?... etc.
The Motley Fool December 18, 2009 Brian Orelli	Swine Flu Just Isn't Bringing Home the Bacon Looks like that one-time boost from sales of swine flu vaccine may not add much to the bottom lines of vaccine makers like GlaxoSmithKline, AstraZeneca, sanofi-aventis, and Novartis.
AskMen.com	1 Million Swine Flu Cases? Swine flu has infected as many as 1 million Americans, U.S. health officials said Thursday, adding that 6 percent or more of some urban populations are infected.
Pharmaceutical Executive December 1, 2005 Anthony Tao	The Avian Few: Is it Too Late for Pharma to Re-enter the Vaccine Fray? Small profit margins and high litigation risks drove most companies out of the vaccine business decades ago. As a possible pandemic looms, pharma re-enters the fray. Is it too late?
Pharmaceutical Executive May 1, 2006 Pasternak et al.	Vaccines: Market on the Rebound The vaccine business was safely inoculated against higher profits. But innovative therapies and looser government controls may spark an outbreak. Are pharmaceuticals ready for this opportunity?